H. Lundbeck A/S
H. Lundbeck A/S increases its share capital by 40,480 shares (0.0206% of outstanding shares) as a result of employee warrant exercise

DGAP-News: H. Lundbeck A/S

2015-02-18 / 21:08

---------------------------------------------------------------------

Valby, Denmark, 18 February 2015 - H. Lundbeck A/S (Lundbeck) today announced
that it has decided to increase its share capital by DKK 202,400, as a
consequence of the exercise of employee warrants. 

The increase is affected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following prices per share of nominally DKK 5: 5,382 shares at DKK 115, 12,666
shares at DKK 102, 18,327 shares at DKK 97 and 4,105 shares at 121. Proceeds to
the company are DKK 4,185,286 (approximately USD 635,608). The increase
corresponds to approximately 0.0206% of the company's share capital. 

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company from the time of
registration of the capital increase, i.e. inter alia full rights to dividends
for the financial year 2014. The new shares will be listed on NASDAQ OMX
Copenhagen after registration with the Danish Business Authority. Lundbeck's
current share capital amounts to DKK 981,944,375 and will after the capital
increase be DKK 982,146,775. The capital increase is expected to be finalized
shortly. 

Lundbeck contacts

Investors:                          Media:                   
                                                             
Palle Holm Olesen                   Mads Kronborg            
Vice President, Investor Relations  Director, Media Relations
PALO@lundbeck.com                   MAVK@lundbeck.com        
+45 36 43 24 26                     +45 36 43 30 00          
                                                             
Jens Høyer                                                   
Specialist, Investor Relations                               
JSHR@lundbeck.com                                            
+45 36 43 33 86                                              
                                                             

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in brain diseases. For more than 50 years, we have been at the
forefront of research within neuroscience. Our key areas of focus are alcohol
dependence, Alzheimer's disease, bipolar disorder, depression/anxiety,
epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, stroke and
symptomatic neurogenic orthostatic hypotension (NOH). 

An estimated 700 million people worldwide are living with brain disease and far
too many suffer due to inadequate treatment, discrimination, a reduced number
of working days, early retirement and other unnecessary consequences. Every
day, we strive for improved treatment and a better life for people living with
brain disease - we call this Progress in Mind. 

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 6,000 employees in 57 countries are engaged in the entire
value chain throughout research, development, production, marketing and sales.
Our pipeline consists of several late-stage development programs and our
products are available in more 100 countries. We have research centers in
China, Denmark and the United States and production facilities in China,
Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5
billion in 2014 (EUR 1.8 billion; USD 2.4 billion). 

For additional information, we encourage you to visit our corporate site
www.lundbeck.com.
News Source: NASDAQ OMX



---------------------------------------------------------------------

2015-02-18 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English          
Company:     H. Lundbeck A/S  
 
 
             Denmark          
ISIN:        DK0010287234     
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
324875 2015-02-18